跳至主要内容
临床试验/NCT00747253
NCT00747253已完成1 期

AutoLITT™ FIM Trial - A Prospective First-In-Man (FIM) Safety Trial of the AutoLITT Laser Treatment of Recurrent/Progressive Brain Tumors

Monteris Medical4 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2008年8月最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
10
试验地点
4
主要终点
Primary endpoint is safety, as determined by absence of severe clinical toxicity or procedure-related neurological deficits

研究概览

简要总结

The main purpose of this study is to evaluate the safety and performance of the AutoLITT system for the treatment of recurrent/progressive glioblastoma multiforme tumors (GBM).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Previous diagnosis of GBM treated with radiotherapy with or without surgical resection and/or chemotherapy
  • Clinical/radiographic suspicion of tumor recurrence/progression

排除标准

  • Previous treatment of target GBM with stereotactic radiosurgery, brachytherapy, or carmustine impregnated wafers (Gliadel).

结局指标

主要结局

Primary endpoint is safety, as determined by absence of severe clinical toxicity or procedure-related neurological deficits

时间窗: 14 days post-surgery

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验

Monteris AutoLITT™ FIM Safety Trial for... | 临床试验